Podrobný výpis o publikaci

CIBULA, David, Huseyin AKILLI, Jiří JARKOVSKÝ, Luc VAN LONKHUIJZEN, Giovanni SCAMBIA, Mehmet Mutlu MEYDANLI, David Isla ORTIZ, Henrik FALCONER, Nadeem R ABU-RUSTUM, Diego ODETTO, Jaroslav KLAT, dos Reis RICARDO, Ignacio ZAPARDIEL, Di Martino GIAMPAOLO, Jiri PRESL, Rene LAKY, Aldo LOPEZ, Vít WEINBERGER, Andreas OBERMAIR, Rene PAREJA, Renata PONCOVA, Constantijne MOM, Nicolo BIZZARRI, Martina BORCINOVA, Koray ASLAN, Rosa Angelica Salcedo HERNANDEZ, Guus FONS, Klára BENEŠOVÁ, Lukas DOSTALEK a Ali AYHAN. Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study. Gynecologic oncology. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023, roč. 170, March 2023, s. 195-202. ISSN 0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2023.01.014.

Další formáty: BibTeX LaTeX RIS

TY  - JOUR
ID  - 2292977
AU  - Cibula, David - Akilli, Huseyin - Jarkovský, Jiří - van Lonkhuijzen, Luc - Scambia, Giovanni - Meydanli, Mehmet Mutlu - Ortiz, David Isla - Falconer, Henrik - Abu-Rustum, Nadeem R - Odetto, Diego - Klat, Jaroslav - Ricardo, dos Reis - Zapardiel, Ignacio - Giampaolo, Di Martino - Presl, Jiri - Laky, Rene - Lopez, Aldo - Weinberger, Vít - Obermair, Andreas - Pareja, Rene - Poncova, Renata - Mom, Constantijne - Bizzarri, Nicolo - Borcinova, Martina - Aslan, Koray - Hernandez, Rosa Angelica Salcedo - Fons, Guus - Benešová, Klára - Dostalek, Lukas - Ayhan, Ali
PY  - 2023
TI  - Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
JF  - Gynecologic oncology
VL  - 170
IS  - March 2023
SP  - 195-202
EP  - 195-202
PB  - ACADEMIC PRESS INC ELSEVIER SCIENCE
SN  - 00908258
KW  - Cervical cancer
KW  - Intermediate risk
KW  - GOG criteria
KW  - Radial surgery
KW  - Adjuvant treatment
KW  - Radiotherapy
UR  - https://www.sciencedirect.com/science/article/pii/S0090825823000148?via%3Dihub
N2  - Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy. (c) 2023 Elsevier Inc. All rights reserved.
ER  -

Základní údaje
Originální název	Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
Autoři	CIBULA, David (203 Česká republika, garant), Huseyin AKILLI, Jiří JARKOVSKÝ (203 Česká republika, domácí), Luc VAN LONKHUIJZEN, Giovanni SCAMBIA, Mehmet Mutlu MEYDANLI, David Isla ORTIZ, Henrik FALCONER, Nadeem R ABU-RUSTUM, Diego ODETTO, Jaroslav KLAT (203 Česká republika), dos Reis RICARDO, Ignacio ZAPARDIEL, Di Martino GIAMPAOLO, Jiri PRESL (203 Česká republika), Rene LAKY, Aldo LOPEZ, Vít WEINBERGER (203 Česká republika, domácí), Andreas OBERMAIR, Rene PAREJA, Renata PONCOVA (203 Česká republika), Constantijne MOM, Nicolo BIZZARRI, Martina BORCINOVA (203 Česká republika), Koray ASLAN, Rosa Angelica Salcedo HERNANDEZ, Guus FONS, Klára BENEŠOVÁ (203 Česká republika, domácí), Lukas DOSTALEK (203 Česká republika) a Ali AYHAN.
Vydání	Gynecologic oncology, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023, 0090-8258.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30214 Obstetrics and gynaecology
Stát vydavatele	Spojené státy
Utajení	není předmětem státního či obchodního tajemství
WWW	URL
Impakt faktor	Impact factor: 4.700 v roce 2022
Kód RIV	RIV/00216224:14110/23:00131019
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.1016/j.ygyno.2023.01.014
UT WoS	000940806800001
Klíčová slova anglicky	Cervical cancer; Intermediate risk; GOG criteria; Radial surgery; Adjuvant treatment; Radiotherapy
Štítky	14110240, 14119612, rivok
Příznaky	Mezinárodní význam, Recenzováno
Změnil	Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 21. 6. 2023 08:45.

Anotace
Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy. (c) 2023 Elsevier Inc. All rights reserved.

Anotace

Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy. (c) 2023 Elsevier Inc. All rights reserved.